Medicines
Prosonix is the world leader in use of ultrasonic pharmaceutical particle engineering technologies for the manufacture of high value pharmaceutical powders and Making Better Medicines. Our pipeline addresses the fast-growing market sectors of asthma, COPD and other respiratory disorders, as well as niche opportunities in orally and parentally delivered products. Prosonix proprietary technologies can be used for API manufacture at any scale.
Particles
Prosonitron™, DISCUS®, UMAX®, SAX™ and PRT based process technologies are proprietary “Solution-to-Particle” methods for controlling crystal size, shape and polymorph for APIs, aimed at Making Better Medicines. Technologies offer dose-to-dose uniformity, formulation consistency, stability and 200% performance increase of inhaled APIs compared to micronized. Combination particles of multiple APIs can be manufactured.
Ultrasound
Power ultrasound facilitates controlled and reproducible crystal nucleation which is fundamental in controlling crystallization. Sonocrystallization delivers controlled nucleation and superior control of particle size, morphology, polymorphism, crystallinity and purity, and in doing so helps eliminate the need for troublesome external seeding and micronization for inhaled medicines.
SonoLab
Multipurpose laboratory equipment for sonocrystallization & sonochemistry are now available. These highly effective and flexible research tools facilitate 100ml – 100L operational capability in batch or continuous operation and can be integrated with automated laboratory reactors. The unique designs allow seamless transition and scale up to Prosonitron™ technology for commercial scale operation.
Prosonitron
Prosonix provide cGMP & ATEX sonocrystallization Prosonitron™ ultrasonic process and reactor technology. They are aligned with emergent FDA “QbD” and “Design for Intent” philosophy. Our proprietary systems are of modular design for optimum flexibility and are an easy retro-fit to existing equipment. They are proven across scale in API production and can be seen as sustainable green technology.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
More Articles...
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
<< Start < Prev 1 2 Next > End >> |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page 1 of 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Based in Oxford UK, our teams of pharmaceutical scientists and technologists combine to give Prosonix a unique multidisciplinary approach to solving complex pharmaceutical solid-state problems. Prosonix leverages its proprietary intellectual property, patented bespoke equipment, and technologies to deliver long term and sustainable value.
Prosonix is developing a portfolio of engineered pharmaceutical mono and combination inhalation therapy products that offer distinct and significant therapeutic advantages to patients compared with commercial products. 
Our innovative pipeline addresses the large and fast-growing market sectors of asthma, COPD and other respiratory disorders, as well as niche opportunities for a number of novel orally and parentally delivered products.
Prosonix has announced that it has entered into a multi-product co-development and licensing agreement with Trimel Biopharma (a subsidiary of Trimel Biopharma Holdings -Barbados) in order to collaborate in combining Prosonix' particle engineering technology and leadership with Trimel's award winning unit dose, single use, disposable dry powder inhaler technology. For further details please see the following and refer to the attached press release:
Prosonix is pleased to announce the launch of its UMAX® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set to revolutionise respiratory medicine. The proprietary technology has now been demonstrated on over 30 generic and novel drug molecules and combination products.
In just a short space of time since its launch Prosonix has successfully scaled up of the UMAX® particle engineering technology. The scale-up has now been carried out on several APIs in cGMP facilities and importantly demonstrates a seamless transition from laboratory to commercial scale batches, with no loss of formulation performance, independent of delivery platform or device.
David Hipkiss, CEO of Prosonix, recently spoke to in-Pharma technologist.com about the company's recent launch of its new Latest News
Events
Prosonix Blog
Click here to visit the Prosonix Blog where Prosonix experts will post their thoughts on a regular basis. You can also submit your own content here and it will appear automatically in the blog following editor review.
Latest Blog Entries
Popular
Newsflash
| Prosonix is pleased to announce the launch of its UMAX® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set to revolutionise respiratory medicine. The proprietary technology has now been demonstrated on over 30 generic and novel drug molecules and combination products. |
Who's Online
Login Form
Prosonix RSS Resources
Prosonix Quick Search
ISO9000 accreditation
